Role of Angiotensin-converting-enzyme (ACE) inhibitors in NAFLD prevention: A study revealed that the use of ACE inhibitors could be associated with decreased induction of de novo NAFLD post LT (odds ratio, 0.09; 95% confidence interval, 0.01-0.92; P<0.042) (36). Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.